Aditxt, Inc.
ADTX Healthcare Biotechnology
Aditxt, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3,200.00, down 97.6% from fiscal 2024. In the quarter to March 2026, revenue grew 1,120.0%, EPS grew 99.6% and free cash flow grew 60.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ADTX
Aditxt, Inc. (ADTX) EV/Sales
As of 16 October 2026, Aditxt, Inc. (ADTX) trades at a EV/Sales of 73.3×. Over the past ten years it has ranged from −598× (March 2026) to 2,186,190,719× (August 2023); the current reading is higher than 67% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −526× | — |
| FY2024 | 3.6× | 90.77% |
| FY2023 | 1.9× | (100.00%) |
| FY2022 | 766,584,227× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 111× | — |
| Dec 2025 | −526× | — |
| Sep 2025 | 818× | 140.33% |
| Jun 2025 | 340× | 2,143.76% |
| 14 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AZTR Azitra, Inc. compare | −9.3× |
| DRMA Dermata Therapeutics, Inc. compare | n/m |
| LIMN Liminatus Pharma Inc. compare | n/m |
| NCNA NuCana PLC Sponsored ADR compare | n/m |
| ENLV Enlivex Ltd. compare | n/m |
| JUNS Jupiter Neurosciences, Inc. compare | n/m |
| LNAI Lunai Bioworks Inc. compare | 18.7× |
| PCSA Heatwurx Inc. compare | 45.3× |
| ADTX Aditxt, Inc. | 73.3× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)